Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Research Report 2024(Status and Outlook)

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Research Report 2024(Status and Outlook)



Report Overview:

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.

The Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size was estimated at USD 5149.74 million in 2023 and is projected to reach USD 8589.20 million by 2029, exhibiting a CAGR of 8.90% during the forecast period.

This report provides a deep insight into the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the PARP (Poly ADP-Ribose Polymerase) Inhibitor market in any manner.

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

AstraZeneca

Tesaro

Merck & Co

Clovis Oncology

Pfizer

GSK

Zai Lab

Market Segmentation (by Type)

Lynparza

Zejula

Rubraca

Talzenna

Other

Market Segmentation (by Application)

Ovarian Cancer

Breast Cancer

Other

Geographic Segmentation
  • North America (USA, Canada, Mexico)
  • Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
  • South America (Brazil, Argentina, Columbia, Rest of South America)
  • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
  • Overview of the regional outlook of the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market:
Key Reasons to Buy this Report:
  • Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
  • This enables you to anticipate market changes to remain ahead of your competitors
  • You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
  • The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
  • Provision of market value (USD Billion) data for each segment and sub-segment
  • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
  • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
  • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
  • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
  • The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
  • Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
  • Provides insight into the market through Value Chain
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • 6-month post-sales analyst support
Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the PARP (Poly ADP-Ribose Polymerase) Inhibitor Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of PARP (Poly ADP-Ribose Polymerase) Inhibitor
1.2 Key Market Segments
1.2.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Type
1.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Overview
2.1 Global Market Overview
2.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competitive Landscape
3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers (2019-2024)
3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturers (2019-2024)
3.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price by Manufacturers (2019-2024)
3.5 Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Sites, Area Served, Product Type
3.6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Competitive Situation and Trends
3.6.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Concentration Rate
3.6.2 Global 5 and 10 Largest PARP (Poly ADP-Ribose Polymerase) Inhibitor Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Chain Analysis
4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2019-2024)
6.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Market Share by Type (2019-2024)
6.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2019-2024)
7 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Sales by Application (2019-2024)
7.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (M USD) by Application (2019-2024)
7.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Application (2019-2024)
8 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segmentation by Region
8.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region
8.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region
8.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region
8.2 North America
8.2.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 AstraZeneca
9.1.1 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Basic Information
9.1.2 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Overview
9.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Market Performance
9.1.4 AstraZeneca Business Overview
9.1.5 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor SWOT Analysis
9.1.6 AstraZeneca Recent Developments
9.2 Tesaro
9.2.1 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Basic Information
9.2.2 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Overview
9.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Market Performance
9.2.4 Tesaro Business Overview
9.2.5 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor SWOT Analysis
9.2.6 Tesaro Recent Developments
9.3 Merck and Co
9.3.1 Merck and Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Basic Information
9.3.2 Merck and Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Overview
9.3.3 Merck and Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Market Performance
9.3.4 Merck and Co PARP (Poly ADP-Ribose Polymerase) Inhibitor SWOT Analysis
9.3.5 Merck and Co Business Overview
9.3.6 Merck and Co Recent Developments
9.4 Clovis Oncology
9.4.1 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Basic Information
9.4.2 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Overview
9.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Market Performance
9.4.4 Clovis Oncology Business Overview
9.4.5 Clovis Oncology Recent Developments
9.5 Pfizer
9.5.1 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Basic Information
9.5.2 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Overview
9.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Recent Developments
9.6 GSK
9.6.1 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Basic Information
9.6.2 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Overview
9.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Market Performance
9.6.4 GSK Business Overview
9.6.5 GSK Recent Developments
9.7 Zai Lab
9.7.1 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Basic Information
9.7.2 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Overview
9.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Market Performance
9.7.4 Zai Lab Business Overview
9.7.5 Zai Lab Recent Developments
10 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Region
10.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Forecast
10.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Forecast by Country
10.2.3 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Forecast by Region
10.2.4 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type (2025-2030)
11.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type (2025-2030)
11.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Application (2025-2030)
11.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (Kilotons) Forecast by Application
11.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings